{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:46:25Z","timestamp":1791009985837,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2025-02213626"],"award-info":[{"award-number":["RS-2025-02213626"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2025-02213626"],"award-info":[{"award-number":["RS-2025-02213626"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]},{"name":"Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea","award":["RS-2024-00337146"],"award-info":[{"award-number":["RS-2024-00337146"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Potent cellular immune responses are crucial for the development of effective vaccines against cancer and chronic infectious diseases. Here, we formulate Nexavant (NVT), a well-characterized TLR3 agonist, into lipid nanoparticles (LNPs) using either the ionizable lipid SM-102 or the cationic lipid DOTAP, and characterize their physicochemical properties and adjuvant potential. Both formulations achieve high encapsulation efficiency and enhance cellular uptake. In contrast to the stronger in vitro potency of DOTAP-based NVT\/LNPs, SM-102\u2013based NVT\/LNPs (NVT\/SM-LNPs) induce greater dendritic cell activation, cytokine production, and systemic T cell responses in vivo, likely due to more efficient delivery of NVT to the spleen. As an adjuvant for peptide vaccines, NVT\/SM-LNP enhances antigen-specific CD4\u207a and CD8\u207a T cell responses and demonstrates potent therapeutic efficacy across subcutaneous, orthotopic, and metastatic TC-1 and B16-OVA tumor models, while also reducing viral titers in a chronic LCMV infection model. Compared to conventional adjuvants (poly(I:C), CpG, GM-CSF, IFA) and current mRNA vaccine platforms at clinically relevant doses, NVT\/SM-LNP elicits stronger T cell immunity and enables effective neoantigen responses without requiring peptide-carrier conjugation. These findings establish NVT\/SM-LNP as a potent adjuvant for T cell\u2013targeted vaccines, with the lipid composition critically influencing immune targeting and efficacy, thereby guiding the design of next-generation vaccines.<\/jats:p>","DOI":"10.1038\/s41541-025-01349-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:37:09Z","timestamp":1766475429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses"],"prefix":"10.1038","volume":"11","author":[{"given":"Kwang Hyun","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Myung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Suk","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bi","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Shik","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Beom","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"1349_CR1","volume":"5","author":"R Wang","year":"2024","unstructured":"Wang, R. et al. The interaction of innate immune and adaptive immune system. Med. Comm. 5, e714 (2024).","journal-title":"Med. Comm."},{"key":"1349_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1075291","volume":"14","author":"KH Ko","year":"2023","unstructured":"Ko, K. H. et al. A novel defined TLR3 agonist as an effective vaccine adjuvant. Front Immunol. 14, 1075291 (2023).","journal-title":"Front Immunol."},{"key":"1349_CR3","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/cancers15245752","volume":"15","author":"SH Lee","year":"2023","unstructured":"Lee, S. H. et al. The defined TLR3 agonist, nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody Therapy By Enhancing Immune Cell Infiltration. Cancers (Basel) 15, 5752 (2023).","journal-title":"Cancers (Basel)"},{"key":"1349_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54620-4","volume":"15","author":"KH Ko","year":"2024","unstructured":"Ko, K. H. et al. A vaccine platform targeting lung-resident memory CD4(+) T-cells provides protection against heterosubtypic influenza infections in mice and ferrets. Nat. Commun. 15, 10368 (2024).","journal-title":"Nat. Commun."},{"key":"1349_CR5","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.7150\/thno.77259","volume":"12","author":"HN Jung","year":"2022","unstructured":"Jung, H. N., Lee, S. Y., Lee, S., Youn, H. & Im, H. J. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics 12, 7509\u20137531 (2022).","journal-title":"Theranostics"},{"key":"1349_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","volume":"375","author":"PS Wei","year":"2024","unstructured":"Wei, P. S. et al. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies. J. Control Release 375, 366\u2013388 (2024).","journal-title":"J. Control Release"},{"key":"1349_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/vaccines12070727","volume":"12","author":"Y Lin","year":"2024","unstructured":"Lin, Y., Chen, X., Wang, K., Liang, L. & Zhang, H. An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer. Vaccines (Basel) 12, 727 (2024).","journal-title":"Vaccines (Basel)"},{"key":"1349_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski, A. E. et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4. NPJ Vaccines 10, 73 (2025).","journal-title":"NPJ Vaccines"},{"key":"1349_CR9","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u20132892 e2877 (2021).","journal-title":"Immunity"},{"key":"1349_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J. Pharm. 601, 120586 (2021).","journal-title":"Int J. Pharm."},{"key":"1349_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K Su","year":"2024","unstructured":"Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat. Commun. 15, 5659 (2024).","journal-title":"Nat. Commun."},{"key":"1349_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202300123","volume":"18","author":"X Ma","year":"2023","unstructured":"Ma, X. et al. Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids. Biotechnol. J. 18, e2300123 (2023).","journal-title":"Biotechnol. J."},{"key":"1349_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(01)00455-X","volume":"106","author":"A Lanzavecchia","year":"2001","unstructured":"Lanzavecchia, A. & Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 106, 263\u2013266 (2001).","journal-title":"Cell"},{"key":"1349_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.4049\/jimmunol.1900963","volume":"204","author":"HY Liu","year":"2020","unstructured":"Liu, H. Y., Pedros, C., Kong, K. F., Canonigo-Balancio, A. J. & Altman, A. Protein Kinase C-eta Deficiency Does Not Impair Antiviral Immunity and CD8(+) T Cell Activation. J. Immunol. 204, 2439\u20132446 (2020).","journal-title":"J. Immunol."},{"key":"1349_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat. Med 19, 465\u2013472 (2013).","journal-title":"Nat. Med"},{"key":"1349_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01029-1","volume":"9","author":"AA Al-Omari","year":"2024","unstructured":"Al-Omari, A. A. et al. Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers. NPJ Vaccines 9, 236 (2024).","journal-title":"NPJ Vaccines"},{"key":"1349_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108631","volume":"257","author":"SM Stribbling","year":"2024","unstructured":"Stribbling, S. M., Beach, C. & Ryan, A. J. Orthotopic and metastatic tumour models in preclinical cancer research. Pharm. Ther. 257, 108631 (2024).","journal-title":"Pharm. Ther."},{"key":"1349_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00262-005-0114-6","volume":"55","author":"Z Cui","year":"2006","unstructured":"Cui, Z. & Qiu, F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunother. 55, 1267\u20131279 (2006).","journal-title":"Cancer Immunol. Immunother."},{"key":"1349_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5725-y","volume":"19","author":"SK Maynard","year":"2019","unstructured":"Maynard, S. K. et al. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. BMC Cancer 19, 540 (2019).","journal-title":"BMC Cancer"},{"key":"1349_CR20","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3390\/cancers15153978","volume":"15","author":"Y Heo","year":"2023","unstructured":"Heo, Y. et al. L-pampo, a novel TLR2\/3 agonist, acts as a potent cancer vaccine adjuvant by activating draining lymph node dendritic cells. Cancers (Basel) 15, 3978 (2023).","journal-title":"Cancers (Basel)"},{"key":"1349_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00430-018-0535-4","volume":"207","author":"AA Mehrizi","year":"2018","unstructured":"Mehrizi, A. A., Rezvani, N., Zakeri, S., Gholami, A. & Babaeekhou, L. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB\/c mice. Med Microbiol Immunol. 207, 151\u2013166 (2018).","journal-title":"Med Microbiol Immunol."},{"key":"1349_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","volume":"386","author":"CB Creech","year":"2022","unstructured":"Creech, C. B. et al. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N. Engl. J. Med 386, 2011\u20132023 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1349_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2190690","volume":"19","author":"P Yassini","year":"2023","unstructured":"Yassini, P. et al. Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. Hum. Vaccin Immunother. 19, 2190690 (2023).","journal-title":"Hum. Vaccin Immunother."},{"key":"1349_CR24","doi-asserted-by":"publisher","first-page":"e1031439","DOI":"10.1080\/2162402X.2015.1031439","volume":"4","author":"WW Greenfield","year":"2015","unstructured":"Greenfield, W. W. et al. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2\/3. Oncoimmunology 4, e1031439 (2015).","journal-title":"Oncoimmunology"},{"key":"1349_CR25","first-page":"16","volume":"7","author":"A Bender","year":"2007","unstructured":"Bender, A. et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 7, 16 (2007).","journal-title":"Cancer Immun."},{"key":"1349_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1349-7006.2009.01416.x","volume":"101","author":"M Miyazawa","year":"2010","unstructured":"Miyazawa, M. et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 101, 433\u2013439 (2010).","journal-title":"Cancer Sci."},{"key":"1349_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijbiomac.2022.10.105","volume":"224","author":"S Jiang","year":"2023","unstructured":"Jiang, S. et al. CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development. Int J. Biol. Macromol. 224, 79\u201393 (2023).","journal-title":"Int J. Biol. Macromol."},{"key":"1349_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/ph16070923","volume":"16","author":"ML Nordin","year":"2023","unstructured":"Nordin, M. L. et al. Peptide-based vaccine against breast cancer: recent advances and prospects. Pharmaceuticals (Basel) 16, 923 (2023).","journal-title":"Pharmaceuticals (Basel)"},{"key":"1349_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1084\/jem.185.3.453","volume":"185","author":"MB Bloom","year":"1997","unstructured":"Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med 185, 453\u2013459 (1997).","journal-title":"J. Exp. Med"},{"key":"1349_CR30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","volume":"20","author":"A Marabelle","year":"2014","unstructured":"Marabelle, A., Kohrt, H., Caux, C. & Levy, R. Intratumoral immunization: a new paradigm for cancer therapy. Clin. Cancer Res 20, 1747\u20131756 (2014).","journal-title":"Clin. Cancer Res"},{"key":"1349_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"1349_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"1349_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.it.2014.04.006","volume":"35","author":"P Andersen","year":"2014","unstructured":"Andersen, P. & Woodworth, J. S. Tuberculosis vaccines-rethinking the current paradigm. Trends Immunol. 35, 387\u2013395 (2014).","journal-title":"Trends Immunol."},{"key":"1349_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0952-7915(98)80119-2","volume":"10","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J., Murali-Krishna, K., Blattman, J. N. & Ahmed, R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10, 444\u2013449 (1998).","journal-title":"Curr. Opin. Immunol."},{"key":"1349_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/2159-8290.CD-18-1357","volume":"9","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. & Wu, C. J. Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 9, 476\u2013481 (2019).","journal-title":"Cancer Discov."},{"key":"1349_CR36","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."},{"key":"1349_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1349_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko, A. V., Khan, M. M., Zhen, X., Tang, Y. & Tao, W. Clinical advances of mRNA vaccines for cancer immunotherapy. Med 6, 100562 (2025).","journal-title":"Med"},{"key":"1349_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10719-023-10100-3","volume":"40","author":"F Micoli","year":"2023","unstructured":"Micoli, F., Romano, M. R., Carboni, F., Adamo, R. & Berti, F. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj. J. 40, 135\u2013148 (2023).","journal-title":"Glycoconj. J."},{"key":"1349_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110972","volume":"133","author":"H Du","year":"2021","unstructured":"Du, H., Xu, T. & Cui, M. cGAS-STING signaling in cancer immunity and immunotherapy. Biomed. Pharmacother. 133, 110972 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"1349_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202306892","volume":"20","author":"A Lamoot","year":"2024","unstructured":"Lamoot, A. et al. Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity. Small 20, e2306892 (2024).","journal-title":"Small"},{"key":"1349_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301687","volume":"12","author":"Z Zhong","year":"2023","unstructured":"Zhong, Z. et al. Lipid Nanoparticle Delivery Alters the Adjuvanticity of the TLR9 Agonist CpG by Innate Immune Activation in Lymphoid Tissue. Adv. Health. Mater. 12, e2301687 (2023).","journal-title":"Adv. Health. Mater."},{"key":"1349_CR43","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3389\/fimmu.2019.03018","volume":"10","author":"S Shirai","year":"2019","unstructured":"Shirai, S. et al. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus. Front Immunol. 10, 3018 (2019).","journal-title":"Front Immunol."},{"key":"1349_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.virs.2022.06.002","volume":"37","author":"N Luan","year":"2022","unstructured":"Luan, N., Cao, H., Wang, Y., Lin, K. & Liu, C. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix in VZV-primed mice. Virol. Sin. 37, 731\u2013739 (2022).","journal-title":"Virol. Sin."},{"key":"1349_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00551-z","volume":"12","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy. Biomark. Res 12, 2 (2024).","journal-title":"Biomark. Res"},{"key":"1349_CR46","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","volume":"4","author":"MJ Carrasco","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).","journal-title":"Commun. Biol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01349-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:04:49Z","timestamp":1769508289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01349-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01349-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.-H.K. is the Chief Executive Officer of NA Vaccine Institute. The remaining authors are employees of the institute. All authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}